Genetics May Predict GLP-1 Drug Weight Loss and Side Effects

GLP-1 receptor agonists (GLP-1 RAs) like Ozempic and Wegovy are highly effective for weight loss and managing type 2 diabetes. However, individual responses vary significantly, with some patients experiencing substantial weight reduction while others face notable adverse effects such as nausea, vomiting, and even psychiatric adverse events. Despite their widespread use, the underlying reasons for this variability in efficacy and tolerability remain poorly understood, especially regarding the role of individual genetic makeup. This study investigated whether genetic factors influence both the degree of weight loss and the occurrence of adverse effects in patients using GLP-1 RAs.

The study identified several genetic variants significantly associated with both the efficacy and tolerability of GLP-1 receptor agonists. Specifically, certain genetic profiles were linked to a greater magnitude of weight loss, while others were correlated with an increased risk of adverse effects, including common gastrointestinal issues and potentially psychiatric adverse events. The most important finding was the clear demonstration that an individual's genetic makeup plays a substantial role in predicting their response to GLP-1 RA therapy, indicating that genetic factors can explain a significant portion of the observed inter-individual variability in treatment outcomes. For instance, patients with specific genetic markers showed a higher likelihood of achieving over 10% body weight reduction, whereas others with different markers had a 2-fold increased risk of experiencing severe nausea or anxiety. This suggests a personalized genetic signature could predict who responds best and who is more prone to side effects.